Profile
James E.
Audia is currently the Director at Ribon Therapeutics, Inc. and a Member at Alzheimer's Association.
Previously, he served as the Independent Director at Constellation Pharmaceuticals, Inc. from 2011 to 2021.
He was also the Executive Director at Chicago Biomedical Consortium from 2017 to 2019.
Additionally, he held the position of Head-Chemistry at Karuna Therapeutics, Inc. from 2019 to 2024.
Dr. Audia obtained his doctorate degree from Yale University and the University of South Carolina.
James E. Audia active positions
| Companies | Position | Start |
|---|---|---|
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops cacner therapies | Director/Board Member | 2018-03-31 |
Alzheimer’s Association
Alzheimer’s Association Miscellaneous Commercial ServicesCommercial Services Noncommercial Research Organizations | Corporate Officer/Principal | 2019-12-31 |
Former positions of James E. Audia
| Companies | Position | End |
|---|---|---|
| KARA THER | Corporate Officer/Principal | 2024-03-17 |
| CONSTELLATION PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 2017-06-30 |
Chicago Biomedical Consortium | Director/Board Member | 2019-09-30 |
Training of James E. Audia
Experiences
Positions held
Active
Inactive
Listed companies
Private companies
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 7 |
|---|---|
Yale University
Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of South Carolina
University of South Carolina Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Alzheimer’s Association
Alzheimer’s Association Miscellaneous Commercial ServicesCommercial Services Noncommercial Research Organizations | Commercial Services |
Constellation Pharmaceuticals, Inc.
Constellation Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers and develops novel drugs targeting regulators of epigenetic function | Health Technology |
Karuna Therapeutics, Inc.
Karuna Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops medicines for psychiatric and neurological disorders like schizophrenia and Alzheimer’s disease | Health Technology |
Ribon Therapeutics, Inc.
Ribon Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical stage biotechnology company that develops cacner therapies | Health Technology |
Chicago Biomedical Consortium |
- Stock Market
- Insiders
- James E. Audia
















